

## IH Quality Improvement (QI) Data Collection Tool

- This tool is intended support data collection for the “[Infantile Hemangioma CPG QI Metrics](#)” published with the AAP IH CPG for clinicians utilizing outcome measurement as an implementation strategy.
- Questions 2-6 in this tool are also mapped to the questions in the clinical assessment tool, “[IH Initial Clinical Assessment for Patients < 3mos](#)”, published with the AAP IH CPG.

### 1. Case identification

- 1.1. Patient name: \_\_\_\_\_
- 1.2. Patient DOB: \_\_\_\_\_
- 1.3. Date of patient’s initial IH assessment: \_\_\_\_\_
- 1.4. Patient age at initial assessment: \_\_\_\_\_
- 1.5. If applicable, date of initial consultation with hemangioma specialist: \_\_\_\_\_

### 2. Is the diagnosis of IH confirmed? *(Question 2.a.ii., IH Initial Clinical Assessment for Patients ≤ 3mos)*

- 2.1. **YES:** This patient is included in the denominator for APP IH CPG QI Measures, “Measure 1: Standard Assessment for Risk Stratification of Infantile Hemangioma (IH)” and “Measure 5: Parental Education After Diagnosis”
- 2.2. **NO:** STOP. Patient is excluded from all QI measures

### 3. Did this patient receive a standardized assessment for risk stratification?

*(Question 2.c.ii-vi., IH Initial Clinical Assessment for Patients ≤ 3mos)*

- 3.1. **YES:** This data is included in the numerator for APP IH CPG QI Measures, “Measure 1: Standard Assessment for Risk Stratification of Infantile Hemangioma (IH)” ; continue to Question 4.
- 3.2. **NO:** Continue to Question 4

### 4. After initial assessment, is this patient’s IH risk “Highest”?

*(Question 2.c.iii., IH Initial Clinical Assessment for Patients ≤ 3mos)*

- 4.1. **YES:** Include this patient in the denominators for AAP IH CPG QI Measure 2, Hemangioma Specialist Consultation for Highest/High Risk IH AND Measure 3, Timing of Consultation for “Highest” Risk IH: Within 1 week; continue to question 4.3
- 4.2. **NO:** Continue to question 5.

**4.3. Did this patient receive consultation with a hemangioma specialist?**

*(Question 4.a.ii., IH Initial Clinical Assessment for Patients  $\leq$  3mos)*

4.3.1. **YES:** Include this patient in the numerator for IH CPG QI Measure 2, Hemangioma Specialist Consultation for Highest/High Risk IH; Continue to question 4.4

4.3.2. **NO:** Continue to question 6

**4.4. Was consultation completed within 1 week of the initial assessment?**

*(Question 4.b.iii., IH Initial Clinical Assessment for Patients  $\leq$  3mos)*

4.4.1. **YES:** Include this patient in the numerator for IH CPG QI Measure 3, Timing of Consultation for “Highest” Risk IH: Within 1 week; Continue to question 6

4.4.2. **NO:** Continue to question 6

**5. After initial assessment, is this patient’s IH risk “High”?**

*(Question 2.c.iv., IH Initial Clinical Assessment for Patients  $\leq$  3mos)*

5.1. **YES:** Include this patient in the denominator for AAP IH CPG QI Measure 2, Hemangioma Specialist Consultation for Highest/High Risk IH AND Measure 4, Timing of consultation for “High” Risk IH: Within 2 weeks; continue to question 5.3

5.2. **NO:** Continue to question 6

**5.3. Did this patient receive consultation with a hemangioma specialist?**

*(Question 4.b.ii., IH Initial Clinical Assessment for Patients  $<$  3mos)*

5.3.1. **YES:** Include this patient in the numerator for IH CPG QI Measure 2, Hemangioma Specialist Consultation for High Risk IH; Continue to question 5.4

5.3.2. **NO:** Continue to question 6

**5.4. Was this consultation completed within 2 weeks of the initial assessment?**

*(Question 4.b.iii., IH Initial Clinical Assessment for Patients  $<$  3mos)*

5.4.1. **YES:** Include this patient in the numerator for IH CPG QI Measure 4, Timing of Consultation for “High” Risk IH: Within 2 weeks; Continue to question 6

5.4.2. **NO:** Continue to question 6

**6. At the initial visit with the primary clinician/practice, did this patient's present caregivers receive standardized information about infantile hemangioma?** *(Question 4.a-d.iv., IH Initial Clinical Assessment for Patients  $\leq$  3mos)*

**6.1. YES:** Include this patient in the numerator for IH CPG QI Measure 5, Parental Education After Diagnosis; Continue to question 7

**6.2. NO:** Continue to question 7

**7. Was/is this patient being treated with oral propranolol?**

*(Perform chart review for visit resulting in initiation of oral propranolol treatment)*

**7.1. YES:** Include this patient in the denominator for IH CPG QI Measure 6, Parental Education For Oral Propranolol Therapy; Continue to question 7.3

**7.2. NO**

**7.3. For all encounters involving IH management AND initiation/continuation of oral propranolol therapy, did this patient's present caregivers receive standardized education about treatment with oral propranolol?**

*(Perform chart review of all visits involving management of IH AND initiation/continuation of oral propranolol therapy. "YES" means that documentation for all such visits includes evidence of standardized education consistent with the measure aim definition.*

**7.3.1. YES:** Include this patient in the numerator for IH CPG QI Measure 6, Parental Education for Oral Propranolol Therapy

**7.3.2. NO**